Clinical Cancer Research, Vol 4, Issue 9 2103-2109, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7

MA Steller, KJ Gurski, M Murakami, RW Daniel, KV Shah, E Celis, A Sette, EL Trimble, RC Park and FM Marincola
Section of Gynecologic Oncology, Surgery Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland 20892, USA. msteller@wihri.org

Human papillomavirus (HPV) infection has been causally associated with cervical cancer. We tested the effectiveness of an HLA-A*0201-restricted, HPV-16 E7 lipopeptide vaccine in eliciting cellular immune responses in vivo in women with refractory cervical cancer. In a nonrandomized Phase I clinical trial, 12 women expressing the HLA-A2 allele with refractory cervical or vaginal cancer were vaccinated with four E786-93 lipopeptide inoculations at 3-week intervals. HLA-A2 subtyping was also performed, and HPV typing was assessed on tumor specimens. Induction of epitope-specific CD8+ T-lymphocyte (CTL) responses was analyzed using peripheral blood leukapheresis specimens obtained before and after vaccination. CTL specificity was measured by IFN-gamma release assay using HLA-A*0201 matched target cells. Clinical responses were assessed by physical examination and radiographic images. All HLA-A*0201 patients were able to mount a cellular immune response to a control peptide. E786-93-specific CTLs were elicited in 4 of 10 evaluable HLA-A*0201 subjects before vaccination, 5 of 7 evaluable HLA-A*0201 patients after two vaccinations, and 2 of 3 evaluable HLA-A*0201 cultures after all four inoculations. Two of three evaluable patients' CTLs converted from unreactive to reactive after administration of all four inoculations. There were no clinical responses or treatment toxicities. The ability to generate specific cellular immune responses is retained in patients with advanced cervical cancer. Vaccination with a lipidated HPV peptide epitope appears capable of safely augmenting CTL reactivity. Although enhancements of cellular immune responses are needed to achieve therapeutic utility in advanced cervical cancer, this approach might prove useful in treating preinvasive disease.

This article has been cited by other articles:

				M. J.P. Welters, G. G. Kenter, S. J. Piersma, A. P.G. Vloon, M. J.G. Lowik, D. M.A. Berends-van der Meer, J. W. Drijfhout, A. R. P.M. Valentijn, A. R. Wafelman, J. Oostendorp, et al. Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine Clin. Cancer Res., January 1, 2008; 14(1): 178 - 187. [Abstract] [Full Text] [PDF]

				D.-W. Liu, Y.-C. Yang, H.-F. Lin, M.-F. Lin, Y.-W. Cheng, C.-C. Chu, Y.-P. Tsao, and S.-L. Chen Cytotoxic T-Lymphocyte Responses to Human Papillomavirus Type 16 E5 and E7 Proteins and HLA-A*0201-Restricted T-Cell Peptides in Cervical Cancer Patients J. Virol., March 15, 2007; 81(6): 2869 - 2879. [Abstract] [Full Text] [PDF]

				D. P. Carbone, I. F. Ciernik, M. J. Kelley, M. C. Smith, S. Nadaf, D. Kavanaugh, V. E. Maher, M. Stipanov, D. Contois, B. E. Johnson, et al. Immunization With Mutant p53- and K-ras-Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome J. Clin. Oncol., August 1, 2005; 23(22): 5099 - 5107. [Abstract] [Full Text] [PDF]

				A. Mahdavi and B. J. Monk Vaccines Against Human Papillomavirus and Cervical Cancer: Promises and Challenges Oncologist, August 1, 2005; 10(7): 528 - 538. [Abstract] [Full Text] [PDF]

				P. J. Baldwin, S. H. van der Burg, C. M. Boswell, R. Offringa, J. K. Hickling, J. Dobson, J. St. C. Roberts, J. A. Latimer, R. P. Moseley, N. Coleman, et al. Vaccinia-Expressed Human Papillomavirus 16 and 18 E6 and E7 as a Therapeutic Vaccination for Vulval and Vaginal Intraepithelial Neoplasia Clin. Cancer Res., November 1, 2003; 9(14): 5205 - 5213. [Abstract] [Full Text] [PDF]

				K. Devaraj, M. L. Gillison, and T.-C. Wu DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA Crit. Rev. Oral. Biol. Med., September 1, 2003; 14(5): 345 - 362. [Abstract] [Full Text] [PDF]

				J. Baines and E. Celis Immune-mediated Tumor Regression Induced by CpG-containing Oligodeoxynucleotides Clin. Cancer Res., July 1, 2003; 9(7): 2693 - 2700. [Abstract] [Full Text] [PDF]

				A. M. Ercolini, J.-P. H. Machiels, Y. C. Chen, J. E. Slansky, M. Giedlen, R. T. Reilly, and E. M. Jaffee Identification and Characterization of the Immunodominant Rat HER-2/neu MHC Class I Epitope Presented by Spontaneous Mammary Tumors from HER-2/neu-Transgenic Mice J. Immunol., April 15, 2003; 170(8): 4273 - 4280. [Abstract] [Full Text] [PDF]

				M. A. Steller Cervical Cancer Vaccines: Progress and Prospects Reproductive Sciences, September 1, 2002; 9(5): 254 - 264. [Abstract] [PDF]

				S. Zwaveling, S. C. F. Mota, J. Nouta, M. Johnson, G. B. Lipford, R. Offringa, S. H. van der Burg, and C. J. M. Melief Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides J. Immunol., July 1, 2002; 169(1): 350 - 358. [Abstract] [Full Text] [PDF]

				M. P. Velders, S. Weijzen, G. L. Eiben, A. G. Elmishad, P.-M. Kloetzel, T. Higgins, R. B. Ciccarelli, M. Evans, S. Man, L. Smith, et al. Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine J. Immunol., May 1, 2001; 166(9): 5366 - 5373. [Abstract] [Full Text] [PDF]

				N. D. Christensen, R. Han, N. M. Cladel, and M. D. Pickel Combination Treatment with Intralesional Cidofovir and Viral-DNA Vaccination Cures Large Cottontail Rabbit Papillomavirus-Induced Papillomas and Reduces Recurrences Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1201 - 1209. [Abstract] [Full Text]

				G. L. Beatty and Y. Paterson IFN-{gamma} Can Promote Tumor Evasion of the Immune System In Vivo by Down-Regulating Cellular Levels of an Endogenous Tumor Antigen J. Immunol., November 15, 2000; 165(10): 5502 - 5508. [Abstract] [Full Text] [PDF]

				L. Muderspach, S. Wilczynski, L. Roman, L. Bade, J. Felix, L. A. Small, W. M. Kast, G. Fascio, V. Marty, and J. Weber A Phase I Trial of a Human Papillomavirus (HPV) Peptide Vaccine for Women with High-Grade Cervical and Vulvar Intraepithelial Neoplasia Who Are HPV 16 Positive Clin. Cancer Res., September 1, 2000; 6(9): 3406 - 3416. [Abstract] [Full Text]

				J. Alexander, M.-F. del Guercio, A. Maewal, L. Qiao, J. Fikes, R. W. Chesnut, J. Paulson, D. R. Bundle, S. DeFrees, and A. Sette Linear PADRE T Helper Epitope and Carbohydrate B Cell Epitope Conjugates Induce Specific High Titer IgG Antibody Responses J. Immunol., February 1, 2000; 164(3): 1625 - 1633. [Abstract] [Full Text] [PDF]

				M. Murakami, K. J. Gurski, F. M. Marincola, J. Ackland, and M. A. Steller Induction of Specific CD8+ T-Lymphocyte Responses Using a Human Papillomavirus-16 E6/E7 Fusion Protein and Autologous Dendritic Cells Cancer Res., March 1, 1999; 59(6): 1184 - 1187. [Abstract] [Full Text] [PDF]